Navigation Links
Cytopia Presentation on VDA CYT997 at AACR Conference
Date:4/15/2009

MELBOURNE, Australia, April 15 /PRNewswire/ -- Cytopia Limited (ASX: CYT) announced that it will present data on its anticancer vascular disrupting agent (VDA) CYT997 at the forthcoming 100th Annual Meeting of the American Association for Cancer Research, in Denver, Colorado, USA.

Dr David Segal, Principal Scientist at Cytopia, will be presenting the poster in the Late-Breaking Research: Experimental and Molecular Therapeutics 2 poster session on Tuesday, April 21, 2009 from 8:00 AM to 2:00 PM (US MDT), Hall BF, Poster Section 26, Poster Board 18.

The poster, entitled CYT997: Preclinical studies on the antivascular effects and mode of action of a Phase II vascular disrupting agent outlines extensive preclinical data for CYT997 which is currently in Phase II clinical studies. Data for CYT997 in a panel of in vitro and in vivo assays will be shown clearly demonstrating the potent antivascular and cytotoxic effects of the compound.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.

Website: www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
2. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
3. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
4. Cytopia and Other Progen Shareholders Maintain Call for Meeting
5. Cytopia Letter to Progen Shareholders
6. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
7. Strategic Diagnostics Updates Roth Conference Presentation Time
8. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
9. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
10. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
11. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
Breaking Biology Technology:
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
Breaking Biology News(10 mins):